Akorn, Inc. (AKRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
AKRX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for AKRX is -37 -- better than just 0.7% of US stocks.
- AKRX's price/sales ratio is 0.02; that's higher than the P/S ratio of merely 0.77% of US stocks.
- In terms of volatility of its share price, AKRX is more volatile than 98.53% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Akorn Inc are SPN, JE, MMLP, SUP, and MX.
- Visit AKRX's SEC page to see the company's official filings. To visit the company's web site, go to www.akorn.com.
AKRX Stock Price Chart Interactive Chart >
AKRX Price/Volume Stats
|Current price||$0.09||52-week high||$5.46|
|Prev. close||$0.18||52-week low||$0.09|
|Day high||$0.20||Avg. volume||9,601,876|
|50-day MA||$0.30||Dividend yield||N/A|
|200-day MA||$2.15||Market Cap||11.98M|
Akorn, Inc. (AKRX) Company Bio
Akorn Inc. manufactures, and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter consumer health products in the United States and internationally. It operates through two segments, Prescription Pharmaceuticals and Consumer Health. The company was founded in 1971 and is based in Lake Forest, Illinois.
AKRX Latest News Stream
|Loading, please wait...|
AKRX Latest Social Stream
View Full AKRX Social Stream
Latest AKRX News From Around the Web
Below are the latest news stories about Akorn Inc that investors may wish to consider to help them evaluate AKRX as an investment opportunity.
(Bloomberg) -- WeWork’s board is scheduled to vote on appointing two new directors on Friday, a critical step in a clash between shareholder SoftBank Group Corp. and a rival faction at the troubled co-working startup.A lawyer for WeWork told Delaware Chancery Court Judge Andre Bouchard in a letter that the company plans a May 29 meeting to fill two empty independent director seats. The nominees are Alex Dimitrief, General Electric Co.’s ex-top lawyer, and Frederick Arnold, the former chief financial officer for Convergex Group.SoftBank and the rival board faction are feuding over the Japanese conglomerate’s decision to scrap a $3 billion deal to buy stock from WeWork’s former Chief Executive Officer Adam Neumann and other shareholders. SoftBank agreed to the purchase last year as it bai...
Moody's Investors Service ("Moody's") downgraded Akorn, Inc.'s ("Akorn") Probability of Default Rating to D-PD from Ca-PD. This follows Akorn's May 20, 2020 announcement that it filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code. Moody's also affirmed Akorn's other existing ratings including the Caa3 Corporate Family Rating and Caa3 senior secured term loan rating.
(Bloomberg) -- Akorn Inc. sought bankruptcy protection from creditors after a series of deficiencies uncovered about its quality-control methods resulted in the collapse of rival Fresenius SA’s buyout of the generic drugmaker and subsequent warning letters from the U.S. Food and Drug Administration.The Lake Forest, Illinois-based company listed as much as $10 billion of debt and $10 billion of assets in its Chapter 11 petition, filed on Wednesday in the Delaware bankruptcy court.In December of 2018, Fresenius SE backed out of its $4.3 billion offer for the company after it discovered issues with Akorn’s pharmaceutical production, quality control and drug testing. A Delaware judge later blessed that decision and is still considering whether Akorn owes Fresenius more than $70 million in d...
Generic drugmaker Akorn Inc filed for bankruptcy protection late Wednesday, citing the overhang of litigation stemming from German healthcare company Fresenius SE's decision two years ago to terminate an over $4 billion acquisition of the company.
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Th...
AKRX Price Returns